Sponsors (82)
The bill gives businesses broader, simpler near-term tax relief for R&E spending and clearer credit rules, but does so with retroactive changes and constraints on switching accounting methods that create compliance costs and planning risks for affected taxpayers.
Businesses (including small businesses) and other taxpayers can immediately deduct research and experimental (R&E) expenses paid or incurred in the year, reducing current taxable income and near-term tax liabilities.
Taxpayers (including firms conducting foreign R&E) face simpler tax treatment because the bill removes the mandatory foreign R&E amortization rule and makes domestic and foreign R&E generally eligible for immediate expensing.
Taxpayers who need to capitalize certain R&E retain flexibility because the bill preserves an elective amortization alternative for capitalized R&E that is not eligible for depreciation.
Taxpayers (particularly those who previously capitalized foreign R&E under the old mandatory amortization rule) may face retroactive tax adjustments and may need to file amended returns or respond to IRS adjustments for years after 2021, producing compliance costs and uncertainty.
Taxpayers who adopt the expensing method will have to stick with that accounting method across years unless the IRS consents, limiting flexibility to change accounting methods and potentially locking firms into suboptimal treatments.
Businesses and small-business owners may see greater year-to-year variability in taxable income because immediate expensing reduces long-term income smoothing, which can complicate tax planning and forecasting.
Based on analysis of 2 sections of legislative text.
Makes immediate expensing the default for qualifying research and experimental expenditures (domestic and foreign) while keeping an elective amortization option for certain capitalized R&E costs.
Allows businesses to immediately deduct (expense) research and experimental (R&E) costs for their trade or business, including qualifying foreign R&E, with an elective amortization option remaining for certain capitalized R&E amounts. Makes conforming changes to how the R&E deduction interacts with the research credit and other cross-references, and applies to taxable years beginning after December 31, 2021.
Introduced March 10, 2025 by Ron Estes · Last progress March 10, 2025